12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

      research-article
      1 , 2 , Reproducibility Project: Cancer Biology
      *
      eLife
      eLife Sciences Publications, Ltd
      methodology, Reproducibility Project: Cancer Biology, IDH, 2-hydroxyglutarate, human

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores ( Errington et al., 2014). This Registered report describes the proposed replication plan of key experiments from ‘Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases’ by Xu and colleagues, published in Cancer Cell in 2011 ( Xu et al., 2011). The key experiments being replicated include Supplemental Figure 3I, which demonstrates that transfection with mutant forms of IDH1 increases levels of 2-hydroxyglutarate (2-HG), Figures 3A and 8A, which demonstrate changes in histone methylation after treatment with 2-HG, and Figures 3D and 7B, which show that mutant IDH1 can effect the same changes as treatment with excess 2-HG. The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.

          DOI: http://dx.doi.org/10.7554/eLife.07420.001

          Related collections

          Most cited references6

          • Record: found
          • Abstract: not found
          • Book: not found

          R: A Language and Environment for Statistical Computing.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.

            Mutations in the IDH1 and IDH2 genes encoding isocitrate dehydrogenases are frequently found in human glioblastomas and cytogenetically normal acute myeloid leukaemias (AML). These alterations are gain-of-function mutations in that they drive the synthesis of the ‘oncometabolite’ R-2-hydroxyglutarate (2HG). It remains unclear how IDH1 and IDH2 mutations modify myeloid cell development and promote leukaemogenesis. Here we report the characterization of conditional knock-in (KI) mice in which the most common IDH1 mutation, IDH1(R132H), is inserted into the endogenous murine Idh1 locus and is expressed in all haematopoietic cells (Vav-KI mice) or specifically in cells of the myeloid lineage (LysM-KI mice). These mutants show increased numbers of early haematopoietic progenitors and develop splenomegaly and anaemia with extramedullary haematopoiesis, suggesting a dysfunctional bone marrow niche. Furthermore, LysM-KI cells have hypermethylated histones and changes to DNA methylation similar to those observed in human IDH1- or IDH2-mutant AML. To our knowledge, our study is the first to describe the generation and characterization of conditional IDH1(R132H)-KI mice, and also the first report to demonstrate the induction of a leukaemic DNA methylation signature in a mouse model. Our report thus sheds light on the mechanistic links between IDH1 mutation and human AML.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

              Mutations of IDH1 and IDH2, which produce the oncometabolite 2-hydroxyglutarate (2HG), have been identified in several tumors, including acute myeloid leukemia. Recent studies have shown that expression of the IDH mutant enzymes results in high levels of 2HG and a block in cellular differentiation that can be reversed with IDH mutant-specific small-molecule inhibitors. To further understand the role of IDH mutations in cancer, we conducted mechanistic studies in the TF-1 IDH2 R140Q erythroleukemia model system and found that IDH2 mutant expression caused both histone and genomic DNA methylation changes that can be reversed when IDH2 mutant activity is inhibited. Specifically, histone hypermethylation is rapidly reversed within days, whereas reversal of DNA hypermethylation proceeds in a progressive manner over the course of weeks. We identified several gene signatures implicated in tumorigenesis of leukemia and lymphoma, indicating a selective modulation of relevant cancer genes by IDH mutations. As methylation of DNA and histones is closely linked to mRNA expression and differentiation, these results indicate that IDH2 mutant inhibition may function as a cancer therapy via histone and DNA demethylation at genes involved in differentiation and tumorigenesis.
                Bookmark

                Author and article information

                Contributors
                Role: Reviewing editor
                Journal
                eLife
                eLife
                eLife
                eLife
                eLife Sciences Publications, Ltd
                2050-084X
                2050-084X
                31 July 2015
                2015
                : 4
                : e07420
                Affiliations
                Science Exchange, Palo Alto , California
                Mendeley , London, United Kingdom
                Science Exchange, Palo Alto , California
                Science Exchange, Palo Alto , California
                Center for Open Science , Charlottesville, Virginia
                [1 ]deptProteomics and Mass Spectrometry Facility , Donald Danforth Plant Science Center , St. Louis, Missouri, United States
                [2 ]University of Virginia , Charlottesville, Virginia, United States
                Institut de Génétique et de Biologie Moléculaire et Cellulaire , France
                Institut de Génétique et de Biologie Moléculaire et Cellulaire , France
                Author notes
                [* ]For correspondence: fraser@ 123456scienceexchange.com
                Article
                07420
                10.7554/eLife.07420
                4521140
                26231040
                f0d1f0e8-66d3-47ed-b3b1-5a900511b026
                © 2015, Evans et al

                This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

                History
                : 11 March 2015
                : 09 July 2015
                Funding
                Funded by: Laura and John Arnold Foundation;
                Award Recipient : Reproducibility Project: Cancer Biology
                The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design or the decision to submit the work for publication.
                Categories
                Registered Report
                Biochemistry
                Human Biology and Medicine
                Custom metadata
                2.3

                Life sciences
                methodology,reproducibility project: cancer biology,idh,2-hydroxyglutarate,human
                Life sciences
                methodology, reproducibility project: cancer biology, idh, 2-hydroxyglutarate, human

                Comments

                Comment on this article